Abstract
Steroid therapy appeared to be a standard treatment for autoimmune pancreatitis (AIP), although some AIP patients improve spontaneously. The indications for steroid therapy in AIP patients are symptoms such as obstructive jaundice, abdominal pain, and back pain, and the presence of symptomatic extrapancreatic lesions. Before steroid therapy, jaundice should be managed by biliary drainage in patients with obstructive jaundice, and blood glucose levels should be controlled in patients with diabetes mellitus. For the initial oral prednisolone dose for induction of remission, 0.6 mg/kg/day is recommended. The initial dose is administered for 2–4 weeks, and the dose is tapered by 5 mg every 1–2 weeks, based on changes in the clinical manifestations, biochemical blood tests (such as liver enzymes and IgG or IgG4 levels), and repeated imaging findings (US, CT, MRCP, ERCP, etc.). The dose is tapered to a maintenance dose (2.5–5 mg/day) over a period of 2–3 months. Steroid therapy should be stopped based on the disease activity in each case. Stopping of maintenance therapy should be planned within at least 3 years in cases with radiological and serological improvement. Re-administration or dose-up of steroid is effective for treating AIP relapses. The prognosis of AIP appears to be good over the short-term with steroid therapy. It is unclear whether the long-term outcome is good because there are many unknown factors, such as relapse, pancreatic exocrine or endocrine dysfunction, and associated malignancy.
References
Wakabayashi T, Kawaura Y, Satomura Y, Watanabe H, Motoo Y, Sawabu N. Long-term prognosis of duct-narrowing chronic pancreatitis. Strategy for steroid treatment. Pancreas. 2005;30:31–9.
Kamisawa T, Yoshiike M, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology. 2005;5:234–40.
Kubota K, Iida H, Fujisawa T, Yoneda M, Inamori M, Abe Y, et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc. 2007;66:1142–51.
Ozden I, Dizdaroglu F, Poyanli A, Emre A. Spontaneous regression of a pancreatic head mass and biliary obstruction due to autoimmune pancreatitis. Pancreatology. 2005;5:300–3.
Araki J, Tsujimoto F, Ohta T, Nakajima Y. Natural course of autoimmune pancreatitis without steroid therapy showing hypoechoic masses in the uncinate process and tail of the pancreas on ultrasonography. J Ultrasound Med. 2006;25:1063–7.
Nishimori I, Okazaki K, Kawa S, Otsuki M. Treatment for autoimmune pancreatitis. J Biliary Tract Pancreas (in Japanese). 2007;28:961–6.
Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol. 2006;41:613–25.
Nishimori I, Okazaki K, Suda K, Kawa S, Kamisawa T, Tanaka S, et al. Treatment for autoimmune pancreatitis. Consensus of treatment for autoimmune pancreatitis by the Research Committee of Intractable Pancreatic Diseases supported by Ministry of Health, Labour and Welfare of Japan. Suizou (in Japanese). 2005;20:343–8.
Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–7.
Kamisawa T, Okamoto A, Wakabayashi T, Watanabe H, Sawabu N. Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome. Scand J Gastroenterl. 2008;43:609–13.
Kamisawa T, Egawa N, Inokuma S, Tsuruta K, Okamoto A, Kamata N, et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas. 2003;27:235–8.
Okazaki K, Kawa S, Kamisawa T, Naruse S, Tanaka S, Nishimori I, et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol. 2006;41:626–31.
Pearson RK, Longnecker DS, Chari ST, Smyrk TC, Okazaki K, Frulloni L, et al. Controversies in clinical pancreatology. Autoimmune pancreatitis: does it exist? Pancreas. 2003;27:1–13.
Ghazale A, Chari ST. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007;56:1650–2.
Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med. 2006;355:2670–6.
Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQβ1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008;134:440–6.
Matsushita M, Yamashina M, Ikeura T, Shimatani M, Uchida K, Takaoka M, et al. Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. Am J Gastroenterol. 2007;102:220–1.
Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Morphological changes after steroid therapy in autoimmune pancreatitis. Scand J Gastroenterol. 2004;11:1154–8.
Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56:1719–24.
Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.
Nishimori I, Otsuki M. Study about steroid therapy for autoimmune pancreatitis. Annual reports of Research Committee of Intractable Pancreatic Diseases supported by Ministry of Health, Labour and Welfare of Japan (in Japanese). 2008;137–44.
Nishino T, Toki F, Oyama H, Shimizu K, Shiratori K. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med. 2006;45:497–501.
Okazaki K, Nichimori I, Uchida K, Otsuki M. Study about indication of therapy and relapse in autoimmune pancreatitis—therapeutic effect and evaluation method of disease activity. Annual reports of the Research Committee of Intractable Pancreatic Diseases supported by Ministry of Health, Labour and Welfare of Japan (in Japanese). 2008;133–6.
Nishimori I, Tamakoshi A, Kawa S, Tanaka S, Takeuchi K, Kamisawa T, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006;32:244–8.
Ito T, Nishimori I, Inoue N, Kawabe K, Gibo J, Arita Y, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;42(Suppl 18):50–8.
Ito T, Kawabe K, Arita Y, Hisano T, Igarashi H, Funakoshi A, et al. Evaluation of pancreatic endocrine and exocrine function in patients with autoimmune pancreatitis. Pancreas. 2007;34:254–9.
Tanaka S, Kobayashi T, Nakanishi K, Okubo M, Murase T, Hashimoto M, et al. Corticosteroid-responsive diabetes mellitus associated with autoimmune pancreatitis. Lancet. 2000;356:910–1.
Weber SM, Cubukcu-Dimopulo O, Palesty JA, Suriawinata A, Klimstra D, Brennan MF, et al. Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma. J Gastrointest Surg. 2003;7:129–37.
Hardacre JM, Iacobuzio-Donahue CA, Sohn TA, Abraham SC, Yeo CJ, Lillemoe KD, et al. Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg. 2003;237:853–9.
Schnelldorfer T, Lewin DN, Adams DB. Long-term results after surgery for autoimmune sclerosing pancreatitis. J Gastrointest Surg. 2007;11:56–8.
Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328:1422–7.
Takayama M, Hamano H, Ochi Y, Saegusa H, Komatsu K, Muraki T, et al. Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol. 2004;99:932–7.
Kamisawa T, Okamoto A. Prognosis of autoimmune pancreatitis. J Gastroenterol. 2007;42(Suppl 18):59–62.
Inoue H, Miyatani H, Sawada Y, Yoshida Y. A case of pancreatic cancer with autoimmune pancreatitis. Pancreas. 2006;33:208–9.
Fukui T, Mitsuya T, Takaoka M, Uchida K, Matsushita M, Okazaki K. Pancreatic cancer associated with autoimmune pancreatitis in remission. Intern Med. 2008;47:151–5.
Ghazale A, Chari S. Is autoimmune pancreatitis a risk factor for pancreatic cancer? Pancreas. 2007;35:376.
Witkiewicz AK, Kennedy EP, Kennedy L, Yeo CJ, Hruban RH. Synchronous autoimmune pancreatitis and infiltrating pancreatic ductal adenocarcinoma: case report and review of the literature. Hum Pathol. 2008;39:1548–51.
Sakashita F, Tanahashi T, Yamaguchi K, Osada S, Sugiyama Y, Adachi Y. Case of pancreatic tail cancer associated with autoimmune pancreatitis. Jpn J Gastroenterol Surg. 2006;39:78–83.
Iida H, Kubota K, Mawatari H, Yoneda M, Goto A, Abe Y, et al. A case of autoimmune pancreatitis developed pancreatic tail cancer. Suizou. 2008;23:608–14.
Kamisawa T, Tsuruta K, Okamoto A, Horiguchi S, Hayashi Y, Xun X, et al. Frequent and significant K-ras mutation in the pancreas, the bile duct, and the gallbladder in autoimmune pancreatitis. Pancreas. 2009;38:890–5.
Acknowledgments
This study was supported by the grant-in-aid for the Refractory Pancreatic Disease from the Ministry of Labor, Health, and Welfare of Japan.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
This article is the third of a three-article series on the Japanese consensus guidelines. The first and second articles are available at doi:10.1007/s00535-009-0184-x and doi:10.1007/s00535-009-0197-5, respectively. Names of committee members are provided in the first article.
Rights and permissions
About this article
Cite this article
Kamisawa, T., Okazaki, K., Kawa, S. et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 45, 471–477 (2010). https://doi.org/10.1007/s00535-010-0221-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-010-0221-9